Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition

Published:2022-03 Issue: Volume:211 Page:112305
ISSN:0927-7765
Container-title:Colloids and Surfaces B: Biointerfaces
language:en
Short-container-title:Colloids and Surfaces B: Biointerfaces

Author:

Ganthala Parimala Devi,Alavala Sateesh,Chella Naveen,Andugulapati Sai Balaji,Bathini Nagendra Babu,Sistla Ramakrishna

Publisher

Elsevier BV

Subject

Colloid and Surface Chemistry,Physical and Theoretical Chemistry,Surfaces and Interfaces,General Medicine,Biotechnology

Reference25 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Erlotinib resistance in lung cancer: current progress and future perspectives;Tang;Front Pharmacol.,2013

3. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway;Jiang;Biomed. Pharmacother.,2017

4. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer;Gorzalczany;Cancer Lett.,2011

5. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors;Cohen;J. Clin. Oncol.,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quercetin and its nanoformulations as promising agents for lung cancer treatment: A focus on molecular mechanisms;Journal of Drug Delivery Science and Technology;2024-09

2. Main chemical constituents and mechanism of anti‐tumor action of Solanum nigrum L;Cancer Medicine;2024-08

3. Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy;Exploration of Medicine;2024-07-14

4. Role and recent progress of P2Y12 receptor in cancer development;Purinergic Signalling;2024-06-14

5. Weaponizing chitosan and its derivatives in the battle against lung cancer;International Journal of Biological Macromolecules;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3